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Abstract: Activation and signalling of estrogen receptor (ER) and COX-2 represent two important pathways in breast 
cancer cell regulation. Activation of either pathway is associated with breast cancer cell proliferation and eventually malig-
nant progression. Raloxifene analogue, Ly117018, a selective estrogen receptor modulator and celecoxib, a speciﬁ  c COX-
2 inhibitor have been shown to inhibit breast cancer cell proliferation when used alone in vitro and in vivo. In this study, 
the combined drug effects on hormone-dependent MCF-7 and hormone-independent MDA-MB-435 cells in vitro were 
evaluated. Cell proliferation assays excluded drug antagonism and revealed a moderate synergistic growth inhibitory activ-
ity of Ly117018 and celecoxib on both cell lines when combined in speciﬁ  c concentrations. Growth inhibition of either 
compound was not associated with cell cycle arrest. In MCF-7 cells, western blot analysis revealed a decreased phos-
phorylation of the AKT protein by either agent alone or in combination. In MDA-MB-435 cells, celecoxib alone induced 
an increase in AKT phosphorylation relative to total AKT protein; this effect was decreased in the presence of Ly117018. 
These results indicate that these two drugs are non-antagonistic; and when combined in speciﬁ  c concentrations, moderate 
synergistic antiproliferative activity of celecoxib and Ly117018 were observed in hormone-dependent MCF-7 and hormone-
independent MDA-MB-435 cells associated with changes in cell cycle distribution and regulation of AKT protein and 
phosphorylation. These ﬁ  ndings further support a central role of the ER- and COX-2 pathways in human breast cancer 
cells.
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Introduction
The central role of estrogen and the estrogen receptor (ER) pathway in the development and progression 
of hormone dependent human breast cancer has been established for decades.
1–5 ER activation in human 
breast cancer cells leads to an increase in cell proliferation mediated at least in part by a higher tran-
scription and bioavailability of growth factors.
2 The modulation of intracellular signalling pathways by 
ER activation inﬂ  uences further molecular mechanisms in favour of cell survival.
6 Reduced susceptibility 
to apoptosis-initiating signals contributes to uncontrolled cell growth.
7 Up to 60% of human breast 
cancer have been shown to be hormone dependent.
8,9 Inhibition of ER dependent tumor cell proliferation 
by antiestrogens represents an effective strategy of targeted therapy.
10 Different molecular mechanisms 
have been identiﬁ  ed mediating this growth inhibition by antiestrogens.
11,12 However, primary or 
secondary antiestrogen resistance is well known in laboratory and clinical settings.
13,14 Further, selective 
estrogen receptor modulators (SERM) have been introduced, some of which like fulvestrant, are being 
used in clinical practice.
15,16 SERMs and estrogen depletion by aromatase inhibitors have been shown 
to overcome tamoxifen resistance
17,18 at least in part and temporarily. Though they are already in 
clinical use, many aspects of how newly developed SERMs or aromatase inhibitors counteract tamoxifen 
resistance have not been elucidated. However, treatment resistance against these drugs has emerged as 
success has been established.
19,20
Hence, further research is required to understand SERM mediated growth inhibition, the development 
of resistance to treatment, and to explore strategies to avoid or overcome this resistance. Ly117018, which 
is a SERM and an analogue of raloxifene has been demonstrated to inhibit ER-positive human breast 
cancer cell proliferation.
21 Raloxifene reduced the incidence of hormone-dependent breast cancer in 
postmenopausal women.
2224
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Lack of ER expression in human breast cancer 
cells is characterised by estrogen independent 
proliferation, and up to 40% of human breast 
cancer represent this phenotype.
8,9,23 Adjuvant 
treatment strategies consist of chemotherapeutics, 
and of trastuzumab in case of positive HER-2 
receptor status. Again, resistance to the selected 
treatment strategy is the major obstacle.
13,24,25 The 
inhibition of cancer induced angiogenesis by 
antibodies or receptor tyrosine kinase inhibitors 
have been added to the palliative breast cancer 
therapy strategies.
26–30
AKT represents a pivotal member in the 
intracellular signalling cascade. AKT is a serine-
threonine kinase activated by phosphorylation.
31,32 
AKT mediates the activation of downstream 
signalling pathways leading to cell proliferation, 
secretion of angiogenic factors, and decreasing the 
susceptibility to apoptotic signals.
33 Beside growth 
factors, estrogen has been shown to activate AKT 
by steroid receptor dependent mechanisms
34,35 and 
by a so-called membrane initiated estrogen 
signalling pathway.
36,35
One strategy to avoid or overcome resistance 
relies on the use of two or more compounds which 
cooperatively inhibit tumor cell proliferation. Cyclo-
oxygenase-2 (COX-2) is one of the key enzymes 
for the catalytic conversion of arachidonic acid to 
prostanoids.
37 Increased COX-2 expression was 
associated with a more malignant phenotype, partly 
due to an increase in the synthesisof angiogenic 
factors, and partly due to the suppression of immu-
nological host responses.
38 COX-2 expression was 
positively correlated with aromatase expression.
39 
Celecoxib is a COX-2 inhibitor which has been 
shown to inhibit proliferation of ER-positive 
and-negative human breast cancer cell lines.
37
Depending on the different molecular targets, 
Ly117018 and celecoxib can be regarded as suitable 
compounds for synergistic antiproliferative activity 
in human breast cancer, especially in ER-positive 
cells; however, based on membrane mediated 
steroid effects, they are also useful in ER-negative 
breast cancer cells.
We hypothesized that the SERM Ly117018 and 
the COX-2 inhibitor celecoxib synergistically 
inhibit cell proliferation of ER-positive MCF-7 
and ER-negative MDA-MB-435 human breast 
cancer cells in vitro. We further hypothesized, that 
the antiproliferative effects are associated with 
either modulation of AKT protein levels or 
phosphorylation.
Material and Methods
Substances
Ly117018 was provided by Eli Lilly, Bad Homburg, 
Ger. A stock solution of 10 mM was prepared in 
ethanol. Celcoxib was provided by Pfizer, 
Karlsruhe, Ger. A stock solution of 10 mM was 
prepared in DMSO.
Antibodies: Anti-AKT and anti-COX-2 were 
obtained from BD Bosciences (San Jose, U.S.A), 
anti-Aktin from Santa Cruz (Santa Cruz, U.S.A), 
anti-pAKT from R&D (Minneapolis, U.S.A), anti 
mouse and anti-rabbit from Cell Signalling New 
England Biolabs (Hitchin, U.K). For signal 
detection, ECL (Amersham, Little Chalfont, U.K) 
chemiluminescence detection system was used.
Cell lines
MCF-7 and MDA-MB-435 cells were provided 
by R. Clarke, Lombardi Cancer Research Center, 
Washington, DC, U.S.A. Cells were maintained 
in RPMI 1640 medium containing L-glutamine, 
10% heat inactivated fetal calf serum (Biokrom, 
Berlin, Ger; the other cell culture compounds were 
derived from PAA Laboratories, Pasching, Austria) 
and penicillin (100 U/ml) and streptomycin 
(100 μg/ml) at 37 °C in a humidiﬁ  ed atmosphere 
with 5% CO2.
Proliferation assay
Cell proliferation assays and analysis were 
performed and analyzed comparably as described 
by Leonessa et al.
40 Cells (10
4/ml) were distrib-
uted in 96 well plates (Greiner, Frickenhausen, 
Ger) and allowed to adhere for 24 hours. Then 
the medium was replaced by fresh medium 
containing vehicle or treatment reagents at the 
indicated concentrations. After the indicated 
treatment period, cells were ﬁ  xed by adding 11% 
glutamate aldehyde (Merck, Darmstadt, Ger) 
solution and stained with 0.05% crystal violet 
(Sigma, Steinheim, Ger) in 25% methanol. After 
washing three times with double distilled water, 
cell bound crystal violet was dissolved by adding 
0.1 M sodium citrate and analyzed using a 
photometer ELISA reader (Tecan, Grödig, Aus-
tria) at 560 nm. The number of adherent cells 
correlates with the crystal violet uptake and 
extinction.
41 At least three independent 
experiments were performed.25
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Calculation of drug synergism
Using the proliferation assay method described 
before, different concentrations of celecoxib and 
Ly117018 were combined. For control, wells 
containing vehicle only, and for calculation wells 
containing single treatment reagents were used. 
Cells were treated for 96 hours and cell content 
was determined as before. The interaction index 
was calculated as described by Tallarida.
42 The 
interaction index (y) was calculated: y = a/A + b/B, 
where a and b represents the concentrations used 
in combination to achieve an antiproliferative 
effect, and A and B represents the concentrations 
of either compound alone to achieve the same 
effect. y   1 indicates drug synergism; y = 1 
indicates an additive drug effect. At least three 
independent experiments were performed.
Cell cycle analysis
MCF-7 (6 × 10
5/well) or MDA-MB-435 (3 × 10
5) 
cells were distributed into 6-well plates (Greiner, 
Frickenhausen, Ger) and allowed to adhere for 
24 hours. The medium was replaced by fresh 
medium containing vehicle or treatment reagents 
at the indicated concentrations. Following 
incubation for 96 hours, cells were harvested and 
ﬁ  xed in 70% ethanol (Roth, Karlsruhe, Ger) at 4 °C 
for one hour. Following washing and treatment 
with RNAse (1 mg/ml stocksolution, Serva, 
Heidelberg, Ger) at 37 °C for 20 minutes, cells 
were stained with 0.01 mg/ml) propidium iodine 
(Calbiochem, Darmstadt, Ger) in PBS (PAA 
Laboratories, Pasching, Austria) containing 0.01% 
NaN3 and 2% FCS for 30 minutes at room 
temperature and light protected. Cell cycle 
distribution was determined using a FACS Calibur 
(BD Biosciences, San Jose, U.S.A) and analyzed 
using Cell Quest pro software (BD Biosciences, 
San Jose, U.S.A). At least three independent 
experiments were performed.
Western blotting 
and immunodetection
Cells (1 × 10
7) were allowed to adhere for 24 hours. 
The medium was replaced and cells were incubated 
with vehicle or indicated treatment reagent 
concentrations for 24 hours. Cells were harvested, 
washed three times in PBS and cell pellets were 
dissolved in lysis buffer (10 mM Tris/HCl ph 8.0, 
140 mM NaCl, 3 mM MgCl2, 1% Triton X-100) 
for 30 minutes at 4 °C. Protein concentrations of 
cell lysates were determined using a Protein Assay 
Kit (Pierce, Rockford, U.S.A.) and 10 μg protein 
per sample were loaded on a denaturing 12.5% 
polyacrylamid gel. Following size separation 
proteins were transferred to a nitrocellulose 
membrane (Schleicher and Schuell, Dassel, Ger). 
The membranes were incubated with the indicated 
primary antibody and subsequently with detecting 
antibody; signal detection was performed using the 
ECL system as described by the manufacturer. 
X-ray ﬁ  lms were developed, (Amersham, Little 
Chalfont, U.K.) scanned and analyzed by Image 
J software.
43,44 Representative blots out of at least 
two independent experiments are shown.
Results
Inhibition of proliferation by single 
compounds
Time dependent growth inhibition of MCF-7 cells 
in vitro by Ly117018 (1 μM) was demonstrated. 
Incubation for up to eight days resulted in 
signiﬁ  cant inhibition of proliferation (Fig. 1A) 
which was detectable as early as day four. The 
medium and reagents were replaced in case of 
longer incubation period after four days. Prolif-
eration of hormone independent MDA-MB-435 
breast cancer cells was not affected by Ly117018 
(1 μM) during the incubation period (Fig. 1A). 
Inhibition of MCF-7 cell proliferation by Ly117018 
was concentration dependent (Fig. 1B), whereas 
MDA-MB-435 cell proliferation was not inﬂ  uenced 
(Fig. 1B).
Celecoxib (50 μM) was shown to inhibit pro-
liferation of both cell lines in a time and dose 
dependent manner. Incubation for up to eight days 
with celecoxib resulted in significant inhibi-
tion of MCF-7 cell proliferation (Fig. 2A) which 
was detected as early as day two. The growth 
inhibitory effect was not caused by sole cytotoxicity, 
since cell number in treated cells slowly increased 
over time as measured by increasing crystal violet 
uptake. The medium and reagents were replaced 
in case of longer incubation period after four 
days. Proliferation of hormone independent 
MDA-MB-435 breast cancer cells was similarly 
affected by celecoxib during the incubation period 
(Fig. 2A). Inhibition of cell proliferation by 
celecoxib was concentration dependent (Fig. 2B) 26
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for both cell lines as shown after an incubation 
period of 96 hours.
Synergism of Ly117018 and celecoxib
Analysis of drug synergism of Ly117018 and cele-
coxib was performed by combining ﬁ  xed concen-
trations of one compound with increasing 
concentrations of the second compound and vice 
versa. Cells were incubated for 96 hours and at 
least three independent experiments were performed 
for each combination. Representative data are 
shown in Figure 3. MCF-7 cells were incubated 
with different concentrations of celecoxib (10 μM, 
20 μM or 30 μM) combined with increasing 
concentrations of Ly117018 ranging from 1 nM to 
1 μM (Fig. 3A). In case of MDA-MB-435 cells, 
different concentrations of Ly117018 (0.3 μM, 
0.6 μM or 1 μM) were incubated with increasing 
concentrations of celecoxib ranging from 0.1 μM 
to 50 μM (Fig. 3B).
The interaction index was calculated for 
different concentration combinations and for both 
cell lines (Table 1). An interaction index  1 indicates 
drug synergism. Ly117018 and celecoxib revealed 
no antagonistic activity with respect to growth 
inhibition of both cell lines. At distinct concentra-
tion combinations of Ly117018 and celecoxib, 
an interaction index value  1 was calculated 
(Table 1).
Effects on cell cycle distribution
After an incubation period of 96 hours, Ly117018 
(0.03 or 0.3 μM) and 10 μM celecoxib revealed 
a mixed response pattern in MCF-7 cells. 
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Figure 1. A) Time dependent inhibition of cell proliferation by 1 μM Ly117018. B) Concentration dependent inhibition of cell proliferation by 
Ly117018 as single agent incubated for 96 hours. Proliferation assays were performed as described in material and methods.% of control 
is related to vehicle treated cells. Data represent mean and standard deviation of three independent experiments. The IC50 in MCF-7 cells 
was 1 μM.27
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Ly117018 as a single agent reduced number of 
cells in G2 and S phase of the cell cycle; 
celecoxib used as a monocompound resulted in 
an increase in the number of cells in G2 and 
S-phase. The combination of both resulted in a 
decrease in the number of cells in G2 and S-phase 
(Fig. 4).
In MDA-MB-435 cells, Ly117018 (0.6 or 
1.0 μM) resulted in a decrease of cell number in 
G2-phase while celecoxib, (30 μM) when used 
alone induced a decrease of cell number in the 
S-phase accompanied by an increase in G2. Given 
together Ly117018 (0.6 μM) and celecoxib 
(30 μM) induced changes in cell cycle distribution 
comparable to the effects induced by celecoxib 
alone. In contrast, 1.0 μM Ly117018 combined 
with 10 μM celecoxib resulted in a cell cycle 
distribution pattern similar to Ly117018 alone 
(Fig. 4).
Effects on AKT protein
The relative amounts of AKT protein and AKT 
phophorylation were investigated by western blotting 
and immunodetection. MCF-7 and MDA-MB-435 
cells were incubated for 24 hours with the indicated 
drug concentrations and combination. In Figure 5, 
the results of one experiment is shown which is 
representative of two independent experiments. 
Detection of beta-Actin served as loading and trans-
fer control. In MCF-7 cells, Ly117018 and celecoxib 
treatment were associated with an increase of AKT 
protein relative to vehicle treated control. In MDA-
MB-435 cells, Ly117018 treatment resulted in a 
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Figure 2. A) Time dependent inhibition of cell proliferation by 50 μM celecoxib. B) Concentration dependent inhibition of cell proliferation by 
celecoxib as single agent incubated for 96 hours. Proliferation assays were performed as described in material and methods.% of control 
is related to vehicle treated cells. Data represent mean and standard deviation of three independent experiments. The IC50 in MCF-7 cells 
was 27 μM, in MDA-MB-435 cells 42 μM.28
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Figure 3. Combined effects of Ly117018 and celecoxib on MCF-7 A) or MDA-MB-435 B) human breast cancer cells. Proliferation assays 
were performed as described in material and methods. Cells were incubated for 96 h. These representative data show for MCF-7 cells the 
combination of increasing concentrations of Ly117018 ranging from 0.001 μM to 1 μM with different deﬁ  ned concentrations of celecoxib 
(10 μM, 20 μM and 30 μM). A) For MDA-MB435 cells, increasing concentrations of celecoxib ranging from 0.01 μM to 50 μM were combined 
with different deﬁ  ned concentrations of Ly117018 (0.3 μM, 0.6 μM and 1 μM). B) Data represent mean and standard deviation of three 
independent experiments.
Table 1. Interaction index, calculated for an incubation period of four days. Single agent concentrations were 
calculated from the experiments showing dose dependent effects (Fig. 2) achieving the same proliferation inhibition 
as combined agents with listed concentrations.
MCF-7
Concentration of 
celecoxib [μM]
Concentration of 
Ly117018 [μM]
Interaction index
10 0.03 0.039
30 0.1 0.76
20 0.03 0.8
MDA-MB-435
30 0.6 0.76
40 0.3 0.88
25 0.3 0.7829
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small increase of AKT protein, whereas celecoxib 
as a single agent led to a marked decrease of AKT 
protein. Ly117018 and celecoxib in combination 
resulted in an increase of AKT protein in MDA-MB-
435 cells compared to celecoxib alone.
Evaluation of pAKT demonstrated a decrease 
of pAKT protein level in MCF-7 cells induced by 
Ly117018, celecoxib or both. Even more, the 
relative amount of phophorylated AKT to total 
AKT decreased upon treatment with Ly117018, 
celecoxib or both (Fig. 6). Evaluation of phos-
phorylated AKT in MDA-MB-435 cells showed a 
marked increase in the relative amount of phos-
phorylated AKT to total AKT due to celecoxib 
treatment alone, which was not detectable in the 
presence of Ly117018 (Fig. 6).
Discussion
The presented data describe for the ﬁ  rst time, the 
combined antiproliferative effects of the SERM 
Ly117018 and the COX-2 inhibitor celecoxib on 
human breast cancer cells in vitro. Using ER-positive 
MCF-7 cells, the results not only exclude an 
antagonism of both compounds but also reveal a 
moderate synergism when combined in speciﬁ  c 
concentrations. The influencing effects of 
Ly117018 and celecoxib on MDA-MB-435 cells 
further point to the notion that SERMs like 
Ly117018 exert biological effects independent of 
ER expression. The results achieved in both cell 
lines support the hypothesis of the interaction of 
different signalling pathways in human breast 
cancer.
Ly117018 and raloxifen have been demonstrated 
to exert antiproliferative effects on human breast 
cancer cell lines in vitro and in vivo.
21,45 IC50 val-
ues were calculated to determine the antiproliferative 
potency of different SERMs.
46 In addition to cell 
cycle perturbation and arrest, the induction of 
apoptosis is a mechanism further associated with 
SERM induced growth inhibition.
47,48
With respect to ER-negative, hormone-
independent breast cancer cell lines, SERMs have 
been demonstrated to exert some antiproliferative 
activity in vitro
49,50 by mechanisms which have not 
been elucidated, although other ﬁ  ndings have been 
published.
51
Celecoxib is a COX-2 inhibitor which has been 
demonstrated to exert antiproliferative effects on 
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ER-positive and-negative human breast cancer cell 
lines in vitro and in vivo.
37 Those published obser-
vations are similar to these ﬁ  ndings demonstrating 
a time and dose dependence of cell growth inhibi-
tion of MCF-7 and MDA-MB-435 cells.
SERMs have been shown to influence the 
arachidonic acid pathway thus inﬂ  uencing the bio-
logical role of COX-2. COX-2 inﬂ  uences aromatase 
expression and downstream molecular signalling 
pathways cross ER-induced cascades.
39,52–54 Eventu-
ally, SERMs might be able to inﬂ  uence molecular 
pathways by membrane mediated steroid effects.
35 
These observations support the necessity to inves-
tigate the interaction of SERMs and COX-2 
inhibitors, mainly to exclude antagonizing effects 
and also for evaluating synergistic activities.
Elevated COX-2 protein levels were demon-
strated in human breast cancer tissues.
55,56 
Increased COX-2 expression was shown to be 
associated with a more malignant phenotype
57 
including the over expression of the HER-2 
receptor activity.
58 In contrast, in ER positive breast 
cancer, elevated COX-2 levels are not associated 
with poor outcome.
59 Additionally, normal epithe-
lial breast tissue surrounding a ductal carcinoma 
in situ (DCIS) contained higher COX-2 levels than 
the DCIS epithelium.
60 In a larger series of normal 
breast tissue, DCIS, and invasive breast cancers, 
COX-2 protein and mRNA levels were lower in 
invasive breast cancer tissues and thus does not 
support the hypothesis correlating increased 
COX-2 levels with malignant progression.
61 Thus, 
COX-2 protein levels and expression might not be 
an appropriate parameter to determine the relevance 
of COX-2 in tumor progression.
COX-2 activation promotes lymphatic invasion 
of breast cancer cells.
62 This was conﬁ  rmed by 
transfection of human breast cancer cells with a 
COX-2 expression vector leading to higher COX-2 
protein levels and a more aggressive phenotype than 
parental cells.
63 COX-2 and prostaglandin E2 
induced the expression of Her-2 receptors character-
izing a more malignant phenotype.
64 Inhibition of 
COX-2 resulted in a decreased Her-2 receptor 31
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expression and also sensitized cells for the anti pro-
liferative effects of trastuzumab.
65 This sensitizing 
potential of COX-2 inhibitors was further conﬁ  rmed 
with respect to doxorubicin treatment, where 
increased anti proliferative effects of doxorubicin 
due to celecoxib were mediated in part by NFkB.
66
Increased COX-2 activity resulted in resistance 
to tamoxifen.
52 Elevated COX-2 activity was not 
associated with reduced doxorubicin or taxane 
sensitivity.
52 The aforementioned observations 
point to the important role of the COX-2 signalling 
pathway and the eicosanoid system in hormone-
dependent and-independent breast cancer cells. 
The relevance is well beyond the angiogenic poten-
tial of COX-2 but also based on the capability to 
interact with estrogen receptor and growth factor 
receptor activated signalling pathways.
67
A more recent comprehensive investigation has 
provided strong evidence that the role of COX-2 
is far from being fully elucidated. Stably trans-
fected COX-2 knockdown Hs578T and 21MT-1 
cells did not change with respect to their proliferative 
or invasive capacity.
61
AKT has a central role in intracellular signalling. 
In MCF-7, cells the inhibition of cell proliferation 
by Ly117018 and celecoxib was associated with a 
decrease of phosphorylated AKT. In ER-negative 
MDA-MB-435 cells, treatment with celecoxib led 
to a decrease of total AKT protein. The decrease 
of total AKT protein was less in the presence of 
both compounds. The decrease of phorshorylated 
AKT observed in MCF-7 cells was not present in 
MDA-MB-435 cells. Celecoxib increased the 
relative amount of phosphorylated AKT protein in 
MDA-MB-435 cells; but this effect was reduced 
upon cotreatment with Ly117018. The effect of 
Ly117018 in MDA-MB-435 cells might be caused 
in part by membrane initiated SERM signalling. 
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In vitro investigations using different human breast 
cancer cell lines demonstrated the reduction of 
AKT activation by celecoxib or Ly117018 
treatment.
68–70 Increased activation of AKT was 
shown to result in an increased estrogen receptor 
alpha activation, which was also attributed for 
causing resistance to tamoxifen.
71 Constitutively, 
increased AKT activation resulted in an upregula-
tion of COX-2 protein.
72 Thus, the interaction of 
the ER- and the COX 2-signalling pathways are of 
further interest.
Celecoxib treatment resulted not only in G0/G1 
arrest and reduction of cells in S-phase, but also in 
the induction of apoptosis.
37,73 Our data revealed 
no G0/G1 arrest in both cell lines due to celecoxib 
treatment. The S-phase proportion is not uniformly 
altered as is obvious from Figure 4. Perturbations 
in cell cycle distribution like G2/M phase accumu-
lation preceding growth inhibition and apoptosis 
were observed in a variety of breast cancer cell lines 
upon treatment with different compounds.
74,75
Targeting the estrogen receptor with SERMs is 
an effective treatment in early and metastasized 
breast cancer, although the problem of SERM 
resistance is an unresolved issue.
18 The relevance 
of COX-2 expression and targeting by COX-2 
inhibitors like celecoxib is an exciting experimen-
tal and clinical research area. Early clinical data 
indicate a chemopreventive and a chemosensitizing 
activity of COX-2 inhibitors in breast cancer.
76,77 
Already initiated or planned clinical trials will fur-
ther elucidate the signiﬁ  cance of COX-2 inhibition 
in prevention and treatment of breast cancer.
77–79
Conclusion
The experimental in vitro data presented herein 
strengthen the notion of the antiproliferative 
potency of the COX-2 inhibitor, celecoxib on 
hormone-dependent and -independent breast 
cancer cells in vitro, conﬁ  rm the growth inhibitory 
activity of the SERM Ly117018 in ER-positive 
breast cancer cells, support the hypothesis of mem-
brane initiated SERM signalling effects, and above 
all exclude drug antagonism of Ly17018 and 
celecoxib in the investigated ER-positive and-
negative human breast cancer cells in vitro.
Abbreviations
ER, estrogen receptor; SERM, selective estrogen 
receptor modulator; pAKT, phosphorylated AKT 
protein; IC, inhibitory concentration.
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